Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Joan Nickerson sold 2,777 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $4.15, for a total transaction of $11,524.55. Following the sale, the insider now owns 17,420 shares in the company, valued at approximately $72,293. The trade was a 13.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Verve Therapeutics Trading Down 11.1 %
VERV traded down $0.37 during trading on Tuesday, hitting $2.97. 2,340,162 shares of the company traded hands, compared to its average volume of 1,441,172. The company has a market cap of $263.72 million, a PE ratio of -1.21 and a beta of 1.86. The stock's 50-day simple moving average is $6.34 and its two-hundred day simple moving average is $5.98. Verve Therapeutics, Inc. has a 1 year low of $2.91 and a 1 year high of $9.31.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. The firm had revenue of $13.08 million during the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Equities analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.
Institutional Trading of Verve Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of Verve Therapeutics by 454.0% during the 1st quarter. GAMMA Investing LLC now owns 33,539 shares of the company's stock valued at $153,000 after acquiring an additional 27,485 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Verve Therapeutics by 4.2% in the 4th quarter. Wellington Management Group LLP now owns 361,498 shares of the company's stock worth $2,039,000 after buying an additional 14,469 shares in the last quarter. California State Teachers Retirement System grew its stake in shares of Verve Therapeutics by 12.5% in the 4th quarter. California State Teachers Retirement System now owns 63,500 shares of the company's stock worth $358,000 after buying an additional 7,046 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of Verve Therapeutics by 81.2% in the 4th quarter. Public Employees Retirement System of Ohio now owns 106,356 shares of the company's stock worth $600,000 after buying an additional 47,656 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Verve Therapeutics by 4.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,818 shares of the company's stock valued at $676,000 after buying an additional 4,777 shares in the last quarter. Institutional investors own 97.11% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on VERV. Royal Bank of Canada reduced their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Verve Therapeutics in a research note on Tuesday, March 25th. William Blair restated an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Guggenheim reiterated a "buy" rating on shares of Verve Therapeutics in a research report on Tuesday, March 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $20.67.
Check Out Our Latest Stock Report on Verve Therapeutics
Verve Therapeutics Company Profile
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
See Also
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
